Get started

KZR

KZR Fib Retracement: Next Target $5 + Big PotentialPlease keep in mind not to take anything I say seriously, as this is of opinion basis and not face value. That being said, let us get to the analysis. I believe through the Fibonacci retracement, we can look at a short target of $5 for the next trend analysis goal of Kezar life sciences. Kezar had a huge decline in price over the past year, but the strong support may out do the negative bids and resistance. They are also expected to go to the next stage of their drug development and testing pipeline before the end of the year (according to their site). It is too early to call a long on this, but given the potential and current support, I am at least calling a short for this with a profit target of $5 being hit soon. It could even pass a $15 threshold in price before the end of the year, but a long call is still too early.
NASDAQ:KZRShort
by gamer456148
KZR - Bullish Divergence Found. Possible Change In MomentumKezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA. SHORT INTEREST 1.12M 08/15/19 P/E Current -1.50 P/E Ratio (with extraordinary items) -2.32 Average Recommendation: BUY Average Target Price: 24.33
NASDAQ:KZRLong
by DEXWireNews